About Galapagos NV

Company Description

We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patientsโ€™ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Year founded

1999

Served area

Worldwide

Headquarters

Generaal De Wittelaan L11 A3, 2800 Mechelen, Antwerpen โ€“ Belgium

Shareholder information

Shares outstanding

65,835,511

IPO

May 6, 2005

Stock exchange(s)

Euronext Brussels

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.